Ultimately, we believe that a TAK1 inhibitor could enhance treatment options for patients with glioblastoma or other tumours showing an immune-activated gene expression signature.” Reference: Damhofer ...

The TAK1 program began in the fall of 2019 and in early 2023, Aqilion signed a pre-clinical licensing- and collaboration deal with Merck KGaA Darmstadt, Germany (10 M€ upfront and 950 M€ in potential ...

EydisBio, an innovative pharmaceutical company dedicated to developing novel treatments for various autoimmune and inflammatory diseases, is excited to announce that it has been awarded a $0.5 ...

Preclinical study data showed that dermal thickening and p-TAK1 expression in the lungs of bleomycin-induced mice were significantly decreased when treated with EYD-001. Fibroinflammatory gene mRNA ...

Preclinical study data showed that dermal thickening and p-TAK1 expression in the lungs of bleomycin-induced mice were significantly decreased when treated with EYD-001. Fibroinflammatory gene mRNA ...

The Food and Drug Administration (FDA) has granted EYD-001, a selective transforming growth factor-β-activated kinase 1 (TAK1) inhibitor, Orphan Drug designation for the treatment of systemic ...

Central to the disease's pathogenesis is the transforming growth factor-β (TGF-β) pathway, with TAK1 playing a pivotal role. Activation of this pathway triggers inflammation and fibrosis, the hallmark ...

When it comes to cancer metastasis, it takes two to tango. That was one of the key findings of a new study led by researchers at Memorial Sloan Kettering Cancer Center (MSK): The TGF-beta and RAS ...

DURHAM, N.C., Aug. 28, 2024 /PRNewswire/ -- EydisBio, an early-stage pharmaceutical company leveraging a novel approach to treating various autoimmune and inflammatory diseases, is thrilled to ...

Background: Tumor Growth Factor β (TGF-β) plays an important role in cancer development. There are three TGF-β isoforms in human: β1, β2, β3. OT-101- an antisense against TGF-β2 – has been shown to be ...

More information: Swarna Bale et al, Pharmacological inhibition of TAK1 prevents and induces regression of experimental organ fibrosis, JCI Insight (2023). DOI: 10.1172/jci.insight.165358 Journal ...